由左心室辅助装置激活的细胞和分子机制
Antonella Galeone1, Cinzia Buccoliero2, Barbara Barile2
1Department of Surgery, Dentistry, Pediatrics and Gynecology, Division of Cardiac Surgery, University of Verona, 37129 Verona, Italy.
International journal of molecular sciences
|January 11, 2024
概括
左心室辅助器件 (LVAD) 为末期心力衰竭提供了最终的治疗方法. 在改善患者健康的同时,LVADs会导致炎症和营养不良等并发症,需要生物标志物识别和营养支持.
科学领域:
- 心脏病学 心脏病学
- 生物医学工程 生物医学工程
- 翻译医学是一种翻译医学.
背景情况:
- 左心室辅助器件 (LVAD) 对于无法移植的末期心力衰竭患者至关重要.
- 尽管设计进步,但LVAD与诸如炎症,纤维化,出血和右心室衰竭等并发症有关.
研究的目的:
- 探索与LVAD支持相关的并发症.
- 为了研究反向重塑在LVAD治疗期间心肌变化的作用.
- 确定用于预测LVAD患者不良事件和潜在治疗点的生物标志物.
主要方法:
- 审查关于LVAD并发症和结果的现有文献.
- 在LVAD支持期间对心肌中的细胞和分子变化的分析.
- 探索在LVAD接受者中风险分层的生物标志物发现.
主要成果:
- 支持LVAD诱导反向重塑与显著的细胞和分子心肌变化.
- 生物标志物正在被确定以预测LVAD患者的不良事件.
- LVAD并发症可能导致或恶化营养不良,建议进行营养干预.
结论:
- LVAD是晚期心力衰竭的重要疗法,但并发症需要谨慎管理.
- 了解心肌变化和识别生物标志物可以导致改善治疗策略.
- 营养支持对于改善LVAD患者的整体健康状况至关重要.
相关概念视频
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Pathophysiology of Cardiac Performance
665
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
665
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
432
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
432


